Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 1/20 | 0.66 |
| ▸ | BCHE | P06276 | 11/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6586809 | 0.88 | LIPE (0.71) | LIPEBCHEL3MBTL1ENPP2HTR1A | |
| SCHEMBL23272706 | 0.87 | LIPE (0.60) | LIPEBCHEKDM4EL3MBTL1ENPP2 | |
| SCHEMBL21300617 | 0.85 | BCHE (0.67) | BCHEKDM4EL3MBTL1HTR1AADRA1D | |
| SCHEMBL14176616 | 0.82 | HTR1A (0.70) | BCHEKDM4EL3MBTL1HTR1AADRA1D | |
| SCHEMBL29954831 | 0.82 | LIPE (0.62) | LIPEL3MBTL1ENPP2HTR1AADRA1D | |
| SCHEMBL18623128 | 0.82 | HTR1A (0.68) | BCHEKDM4EL3MBTL1HTR1AADRA1D | |
| SCHEMBL3757832 | 0.81 | BCHE (0.58) | BCHEKDM4EL3MBTL1HTR1AADRA1D | |
| SCHEMBL19830914 | 0.81 | LIPE (0.60) | LIPEL3MBTL1ENPP2HTR1AADRA1D | |
| SCHEMBL132403 | 0.80 | LIPE (1.00) | LIPEL3MBTL1ENPP2HTR1AADRA1D | |
| SCHEMBL29591898 | 0.80 | LIPE (1.00) | LIPEL3MBTL1ENPP2HTR1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104341386-A | Aryl heterocycle micromolecule compounds, derivatives thereof, and preparing methods and uses of the compounds and the derivatives | SHANGHAI INST MATERIA MEDICA | 2015-02-11 | — | — | CN | disclosed |
| WO-2010138576-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-7687664-B2 | Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1394147-A1 | CARBOXYLIC ACID DERIVATIVE AND MEDICINE COMPRISING SALT OR ESTER OF THE SAME | Eisai Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | GPR119, NR3C1, INSR | LIPE 821/4885BCHE 4034/4885KDM4E 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.